Pure Global AI
NCT06360822Recruiting

Increasing Equity in Lung Cancer Screening

Indiana UniversityClinicalTrials.govbehavioral
Verified
Study focus
Disease/Condition
Lung Cancer
Drug/Device/Intervention
ED-LCS
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Indiana University
Location
Indianapolis, United States of America
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Feb 01, 2027
Enrollment
144 participants
Primary outcome

Rate of patients receive Lung Cancer Screening

Summary

The overall objective of this mixed methods study is to: 1) Refine the Emergency Department
 Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key
 stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy,
 acceptability, and feasibility; and 3) provide an in-depth description of stakeholders'
 experiences with the ED-LCS intervention for future refinement.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06360822
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06360822 through Pure Global AI's free database. This phase not specified trial is sponsored by Indiana University and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 144 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.